Back to Journals » Drug, Healthcare and Patient Safety » Volume 3
Perspectives
![](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Should benefit–risk assessment have its own drug “label”?
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
9,701 | Dovepress* | 8,894+ | 1,842 | 10,736 | |
PubMed Central* | 807 | 159 | 966 | ||
Totals | 9,701 | 2,001 | 11,702 | ||
*Since 3 August 2011 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
7 | 0 | 0 | 0 | 3 | 4 |
View citations on PubMed Central and Google Scholar